BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 23526331)

  • 1. Engraftment of low numbers of pediatric acute lymphoid and myeloid leukemias into NOD/SCID/IL2Rcγnull mice reflects individual leukemogenecity and highly correlates with clinical outcome.
    Woiterski J; Ebinger M; Witte KE; Goecke B; Heininger V; Philippek M; Bonin M; Schrauder A; Röttgers S; Herr W; Lang P; Handgretinger R; Hartwig UF; André MC
    Int J Cancer; 2013 Oct; 133(7):1547-56. PubMed ID: 23526331
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human acute leukemia cells injected in NOD/LtSz-scid/IL-2Rgamma null mice generate a faster and more efficient disease compared to other NOD/scid-related strains.
    Agliano A; Martin-Padura I; Mancuso P; Marighetti P; Rabascio C; Pruneri G; Shultz LD; Bertolini F
    Int J Cancer; 2008 Nov; 123(9):2222-7. PubMed ID: 18688847
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Good engraftment of B-cell precursor ALL in NOD-SCID mice.
    Baersch G; Möllers T; Hötte A; Dockhorn-Dworniczak B; Rübe C; Ritter J; Jürgens H; Vormoor J
    Klin Padiatr; 1997; 209(4):178-85. PubMed ID: 9293448
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of variables determining the engraftment potential of human acute myeloid leukemia in the immunodeficient NOD/SCID human chimera model.
    Rombouts WJ; Martens AC; Ploemacher RE
    Leukemia; 2000 May; 14(5):889-97. PubMed ID: 10803522
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hoechst 33342 Staining Identifies the Progenitor Side Population in NOD.Cg-PrkdcscidIL2rgtmWjl/Sz Mice Harboring Pediatric Leukemias.
    Andre MC; Witte KE; Hoerrmann RA; Schmitt A; Handgretinger R; Ebinger M
    In Vivo; 2015; 29(6):661-9. PubMed ID: 26546522
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved engraftment of human acute myeloid leukemia progenitor cells in beta 2-microglobulin-deficient NOD/SCID mice and in NOD/SCID mice transgenic for human growth factors.
    Feuring-Buske M; Gerhard B; Cashman J; Humphries RK; Eaves CJ; Hogge DE
    Leukemia; 2003 Apr; 17(4):760-3. PubMed ID: 12682634
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Generation of Pediatric Leukemia Xenograft Models in NSG-B2m Mice: Comparison with NOD/SCID Mice.
    Gopalakrishnapillai A; Kolb EA; Dhanan P; Bojja AS; Mason RW; Corao D; Barwe SP
    Front Oncol; 2016; 6():162. PubMed ID: 27446808
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human AML cells in NOD/SCID mice: engraftment potential and gene expression.
    Lumkul R; Gorin NC; Malehorn MT; Hoehn GT; Zheng R; Baldwin B; Small D; Gore S; Smith D; Meltzer PS; Civin CI
    Leukemia; 2002 Sep; 16(9):1818-26. PubMed ID: 12200698
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term observation reveals high-frequency engraftment of human acute myeloid leukemia in immunodeficient mice.
    Paczulla AM; Dirnhofer S; Konantz M; Medinger M; Salih HR; Rothfelder K; Tsakiris DA; Passweg JR; Lundberg P; Lengerke C
    Haematologica; 2017 May; 102(5):854-864. PubMed ID: 28183848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Establishment of human acute B-lymphoblastic leukemia NOD/SCID/IL2 receptor γ chain(null) neonatal mouse xenotransplant model].
    Kong Y; Liu YR; Liu KY; Huang XJ; Ishikawa F; Harada M
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Jun; 20(3):762-8. PubMed ID: 22739198
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early relapse in ALL is identified by time to leukemia in NOD/SCID mice and is characterized by a gene signature involving survival pathways.
    Meyer LH; Eckhoff SM; Queudeville M; Kraus JM; Giordan M; Stursberg J; Zangrando A; Vendramini E; Möricke A; Zimmermann M; Schrauder A; Lahr G; Holzmann K; Schrappe M; Basso G; Stahnke K; Kestler HA; Te Kronnie G; Debatin KM
    Cancer Cell; 2011 Feb; 19(2):206-17. PubMed ID: 21295523
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IMC-EB10, an anti-FLT3 monoclonal antibody, prolongs survival and reduces nonobese diabetic/severe combined immunodeficient engraftment of some acute lymphoblastic leukemia cell lines and primary leukemic samples.
    Piloto O; Nguyen B; Huso D; Kim KT; Li Y; Witte L; Hicklin DJ; Brown P; Small D
    Cancer Res; 2006 May; 66(9):4843-51. PubMed ID: 16651440
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interleukin-27 inhibits the growth of pediatric acute myeloid leukemia in NOD/SCID/Il2rg-/- mice.
    Zorzoli A; Di Carlo E; Cocco C; Ognio E; Ribatti D; Ferretti E; Dufour C; Locatelli F; Montagna D; Airoldi I
    Clin Cancer Res; 2012 Mar; 18(6):1630-40. PubMed ID: 22383738
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A robust xenotransplantation model for acute myeloid leukemia.
    Sanchez PV; Perry RL; Sarry JE; Perl AE; Murphy K; Swider CR; Bagg A; Choi JK; Biegel JA; Danet-Desnoyers G; Carroll M
    Leukemia; 2009 Nov; 23(11):2109-17. PubMed ID: 19626050
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of T-lymphocytic leukemia-initiating stem cells residing in a small subset of patients with acute myeloid leukemic disease.
    Risueño RM; Campbell CJ; Dingwall S; Levadoux-Martin M; Leber B; Xenocostas A; Bhatia M
    Blood; 2011 Jun; 117(26):7112-20. PubMed ID: 21562049
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytokine treatment or accessory cells are required to initiate engraftment of purified primitive human hematopoietic cells transplanted at limiting doses into NOD/SCID mice.
    Bonnet D; Bhatia M; Wang JC; Kapp U; Dick JE
    Bone Marrow Transplant; 1999 Feb; 23(3):203-9. PubMed ID: 10084250
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Absence of IL-12Rβ2 in CD33(+)CD38(+) pediatric acute myeloid leukemia cells favours progression in NOD/SCID/IL2RγC-deficient mice.
    Ferretti E; Montagna D; Di Carlo E; Cocco C; Ribatti D; Ognio E; Sorrentino C; Lisini D; Bertaina A; Locatelli F; Pistoia V; Airoldi I
    Leukemia; 2012 Feb; 26(2):225-35. PubMed ID: 21844875
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EVI-1 modulates leukemogenic potential and apoptosis sensitivity in human acute lymphoblastic leukemia.
    Konantz M; André MC; Ebinger M; Grauer M; Wang H; Grzywna S; Rothfuss OC; Lehle S; Kustikova OS; Salih HR; Handgretinger R; Fend F; Baum C; Kanz L; Quintanilla-Martinez L; Schulze-Osthoff K; Essmann F; Lengerke C
    Leukemia; 2013 Jan; 27(1):56-65. PubMed ID: 22828445
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD34+CD38+CD19+ as well as CD34+CD38-CD19+ cells are leukemia-initiating cells with self-renewal capacity in human B-precursor ALL.
    Kong Y; Yoshida S; Saito Y; Doi T; Nagatoshi Y; Fukata M; Saito N; Yang SM; Iwamoto C; Okamura J; Liu KY; Huang XJ; Lu DP; Shultz LD; Harada M; Ishikawa F
    Leukemia; 2008 Jun; 22(6):1207-13. PubMed ID: 18418410
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Engraftment of human T-cell acute lymphoblastic leukemia in immunodeficient NOD/SCID mice which have been preconditioned by injection of human cord blood.
    Dialynas DP; Shao L; Billman GF; Yu J
    Stem Cells; 2001; 19(5):443-52. PubMed ID: 11553853
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.